Benzinga | Feb 22, 2021 07:56AM EST

Benchmark Downgrades Nektar Therapeutics to Hold, Announces $26 Price Target

Benchmark analyst Aydin Huseynov downgrades Nektar Therapeutics (NASDAQ:NKTR) from Buy to Hold and announces $26 price target.